Home/ Stocks/ ALZN

Alzamend Neuro, Inc. Common Stock

ALZN XNAS

$1.19 -0.03 (-2.46%) ▼ 15-min delayed

Open

$1.16

High

$1.24

Low

$1.16

Volume

19.0K

Market Cap

$4.64M

About Alzamend Neuro, Inc. Common Stock

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 7 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2026	$0	$-2,198,991	$-0.58
Q1 2026	$0	$2.70M	$-1.28
FY 2025	$0	$4.50M	$-11.32
Q3 2025	$0	$-1,039,434	$-0.19

Earnings & Analyst Ratings

Next Earnings: Tue, Sep 8, 2026

Calendar →

Related Market News

No specific coverage for ALZN yet. Check out our latest market news or earnings calendar.

Get ALZN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Alzamend Neuro, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.